- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Transparency report in accordance with §17 Section 2 of the general terms and conditions for open markets
* Best first half of year in company history
* Net asset value increases to nearly EUR 144 million
* Cash influx from BioMicro transaction not yet included
Frankfurt-based nanotechnology company Nanostart AG is reporting the best first-half results since the company was founded for the first six months of 2010. In accordance with commercial code, semi-annual net profit totaled EUR 923,000 (previous year EUR -1.4 million). Earlier in the year, Swiss company and global market leader Roche Diagnostics purchased the main product line of American Nanostart holding BioMicro Systems, Inc. Revenues from this transaction are however not included in semi-annual numbers, as the cash transfer took place after the June 30, 2010 reporting date.
In addition to positive earnings results, Nanostart achieved a net asset value of nearly EUR 144 million as of the reporting date. This is approximately EUR 29 million more than at the same point last year. In the conservative calculation of net asset value, shares of unlisted shareholdings - about 80 percent of the current portfolio - are attributed to acquisition costs in the calculations. Only existing shareholdings in Nanostart AG companies that are listed on the stock exchange are entered at market value.
The company continues to pursue international expansion. Acquisition of additional holdings is anticipated this year, especially in Singapore, where Nanostart is investing as a government partner.
Semi-annual numbers are now archived at the Nanostart website in the Investor Relations area. The 2010 semi-annual report will be available September 27 in the company reports section.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan. If there is any inconsistency between the German and the English versions of this document, the German version will prevail.
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
For more information, please click here
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © NanostartIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016